About
Biosortia Pharmaceuticals develops microbiome-derived small molecule therapeutics that target the gut-brain-immune axis for metabolic diseases such as obesity, as well as other indications like inflammatory bowel disease, CNS disorders, oncology, pain, and anti-infectives.
Explore Biosortia Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.